Table 2 Descriptive data of original articles reviewed
Year | Authors | Sample size | Study design | Outcome |
|---|---|---|---|---|
2021 | Wesley Tyler Abplanalp et al. [27] | 10 | Cohort | • Presence of DNMT3A mutation in the monocytes of heart failure patients has increased the expression of inflammatory genes which might aid the provoke the occurrence of chronic heart failure. |
2021 | Michael C. Honigberg et al. [21] | 19,606 | Cohort | • Association between natural premature menopause and CHIP = P = 0.001 • DNMT3A mutation was observed to be significantly associated with premature menopause • Natural premature menopause might be considered as a risk signal for developing CHIP or CHIP-associated CVD |
2021 | Domingo A. Pascual-Figal et al. [24] | 62 | Cohort | • Presence of DNMT3A or TET2 mutations might accelerate HF progression in terms of death (P = 0.008) |
2020 | Alexander G. Bick et al. [18] | 97,691 | Cohort | • > 75% of CHIP mutations in DNMT3A, TET2, and ASXL1. • 15% of CHIP mutations were in PPM1D, JAK2, SF3B1, SRSF2, and TP53 |
2020 | Alexander G. Bick et al. [20] | 35,416 | Cohort | • CHIP associated with increased CVD event risk (P = 0.019) • Presence of large CHIP mutations adjusted for hSCRP value showed increase in CVD event risk (P = 0.0016) • Presence of rs1880241 shows reduced CVD events in large CHIP carriers (P = 0.025) • IL6R p.Asp358Ala allele reduces CVD event risk in individuals (p = 0.047) |
2020 | Wesley Tyler Abplanalp et al. [19] | 17 | Case-control | • Patients with DNMT3A or TET2 CHIP mutations can be categorized for high risk for adverse outcomes of COVID-19 • SARS-CoV-2 patients could be tested for the presence of DNMT3A or TET2 CHIP-driver sequence variations to provide personalized treatment strategies such as IL-6 or IL-6R antagonists to mitigate CRS |
2020 | Lambert Busque et al. [26] | 1887 | Case-control | • hs-CRP was significantly higher in CHIP carriers (P = 0.009) • DNMT3A CHIP mutation carriers had higher hs-CRP (P = 0.04) |
2020 | Sebastian Cremer et al.25 | 419 | Cohort | Patients with two or more CHIP mutations have increased mortality risk (P < 0.001) as compared to patients with a single CHIP mutation or individuals without mutations. (P < 0.001). |
2019 | Lena Dorsheimer et al. [23] | 200 CHF | Cohort | • DNMT3A ( 7% of patients); TET2 (4.5% of patients), KDM6A (2 % of patients), BCOR (1.5 % of patients) • Significantly worse long-term clinical outcome observed in patients with DNMT3A/TET2mutations |
2017 | S. Jaiswal et al. [22] | 8255 | Case-control study | The presence of CHIP mutation nearly doubled the risk of coronary heart disease in humans and mice with accelerated atherosclerosis. |